Vista Pharmaceuticals (524711) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
14 Aug, 2026Executive summary
Unaudited financial results for the quarter ended June 30, 2026, were approved by the board on August 14, 2026.
The company reported a net loss for the quarter, continuing a multi-year trend of losses.
Financial highlights
Revenue from operations for the quarter was Nil, compared to ₹151.88 lakhs in the same quarter last year.
Loss before tax for the quarter was ₹(132.71) lakhs, versus ₹(148.01) lakhs year-over-year.
Net loss after tax stood at ₹(98.59) lakhs, compared to ₹(129.04) lakhs in the prior year quarter.
Basic and diluted EPS for the quarter were both ₹(0.16), unchanged due to anti-dilutive effect of outstanding warrants.
Current liabilities exceeded current assets by ₹183.32 lakhs as of June 30, 2026.
Outlook and guidance
Management is negotiating debt restructuring and implementing cost rationalization.
A formal financial undertaking from warrant subscribers is expected to provide ₹922.49 lakhs to support operations.
Latest events from Vista Pharmaceuticals
- Audited FY26 results received an unqualified opinion; new internal auditor appointed for FY27.524711
Q4 25/26 - Q3 FY26 saw higher net loss and ECL provision, with statutory dues outstanding.524711Q3 25/26
- Q2 FY26 saw lower revenue, higher losses, and major ECL provisioning amid new capital raised.524711Q2 25/26
- Revenue fell and losses deepened in Q1 FY26, with leadership continuity affirmed.524711Q1 25/26
- Q2 FY25 saw lower revenue but reduced losses and stronger equity from capital raising.524711Q2 24/25
- Q1 FY25 saw lower revenue and a net loss, with AGM scheduled for September 30, 2024.524711Q1 24/25
- Net loss persists despite revenue growth; WHO certification and audit opinion boost credibility.524711Q4 24/25
- Q3 FY25 revenue surged, but losses continued; WHO certification marks a key milestone.524711Q3 24/25